At a glance
ClinicalIndex Comparison RecordN/AUnknown· 100 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)
In Brief
An observational study for Prostate Cancer Metastatic. Targeting 100 participants.
Detailed Summary
The investigators plan to perform multi-omics technologies, including genomic, transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate cancer, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer Metastatic
Countries--
Collaborators--
Timeline
N/AUnknownOverdue
202120222023202420252026
First PostedDec 2020
Enrollment StartAug 2021
Primary CompletionNov 2022
Study CompletionApr 2023
TodayJul 2026
First PostedDec 9, 2020
Enrollment StartAug 1, 2021
Primary CompletionNov 1, 2022
Study CompletionApr 1, 2023
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 5.6 years ago